Thursday, February 25, 2021

Financial News Conference on the Full Year 2020 Results

Bayer delivers robust performance despite pandemic – foundation laid for future growth
  • Group sales at 41.400 billion euros, impacted by negative currency effects of 1.941 billion euros (Fx & portfolio adj. plus 0.6 percent)

  • EBITDA before special items level with prior year at 11.461 billion euros (minus 0.1 percent) – currency effects offset by stringent cost management

  • Crop Science and Pharmaceuticals report stable operational business, Consumer Health sees strong growth

  • Core earnings per share at 6.39 euros (plus 0.2 percent)

  • Earnings per share at minus 10.68 euros (2019: plus 4.17 euros), impacted by litigation provisions and impairments

  • Net financial debt improves by 11.8 percent to 30.041 billion euros

  • Proposed dividend of 2.00 euros per share (2019: 2.80 euros)

  • Portfolio and innovation capabilities strengthened

  • Outlook for 2021: positive momentum and solid operational growth – stable earnings at constant currencies




Follow us:


   You will find the key statements on » Twitter